Ligand Pharmaceuticals Inc (LGNDZ)
LGNDZ is quoted over the counter, not listed on an exchange. Ligand Pharmaceuticals Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Profile
| Field | Value |
|---|---|
| Ticker | LGNDZ, quoted over the counter |
| SEC CIK | 0000886163 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Palm Beach Gardens, FL |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $56.0M cash; operating cash flow $22.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 20,002,986 (2026-10-27); 19,681,720 a year earlier; 17,435,958 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-27 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $33.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $78.7M | -$28.5M | -$27.6M | $56.0M | $1.1B | $253.8M | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $63.7M | $48.5M | $24.0M | $1.0B | $1.1B | $290.5M | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $51.7M | -$13.3M | $48.7M | $115.1M | No debt tags | $274.5M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $59.7M | $44.8M | $45.9M | $174.9M | No debt tags | $268.1M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $115.5M | $117.3M | $13.1M | $139.4M | No debt tags | $251.2M | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $47.6M | $4.8M | $15.8M | $67.7M | No debt tags | $187.6M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $45.3M | -$42.5M | -$25.4M | $48.0M | No debt tags | $181.5M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $42.8M | -$31.1M | $28.5M | $72.3M | No debt tags | $167.1M | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-27 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-05-18 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier